Magic bullets for the 21st century: the reemergence of immunotherapy for multi- and pan-resistant microbes.
In our current world, antibiotic resistance among pathogenic microbes keeps getting worse with few new antibiotics being pursued by pharmaceutical companies. Modern-day immunotherapies, reminiscent of the serotherapy approaches used in the early days of antimicrobial treatments, are a potential counter-measure, but are usually limited by the narrow spectrum against target antigens. Surprisingly, many multidrug-resistant (MDR) bacteria share a common surface polysaccharide, poly-β-1,6-N-acetylglucosamine (PNAG). Natural antibodies to PNAG are present in normal human sera, but are not protective. However, human monoclonal antibodies (MAbs) or polyclonal antisera raised to a deacetylated glycoform of PNAG mediate opsonic killing and protect mice against infections due to all PNAG-positive MDR pathogens tested. An MAb is currently in Phase II clinical trials. These discoveries could lead to utilization of antibodies to PNAG for either therapeutic use in patients infected by PNAG-producing MDR bacteria or prophylactic use in patients at risk of developing MDR infections.
Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital,  Harvard Medical School, Boston, MA,  USA.
Damien
D
Roux
Gerald B
GB
Pier
David
D
Skurnik
D000818:Animals; D000907:Antibodies, Bacterial / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001419:Bacteria / Q000276:immunology*; D001424:Bacterial Infections / Q000382:microbiology / Q000628:therapy*; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016896:Treatment Outcome; D047071:beta-Glucans / Q000276:immunology*
D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D047071:beta-Glucans; C505465:poly-N-acetyl-1-6-glucosamine